organ growth track
challeng fx top end ep
organ growth temper tougher fx abt organ growth
exceed estim factset consensu respect
worse-than-expect fx vs trim mil sale dollar
term penni ep henc in-lin result rank favorit name
among investor recent investor sentiment survey given underli
strength fundament mgmt confirm preliminari organ growth
expect expect stock continu outperform univers
next twelv month given strong potenti acceler growth libr mitraclip
lab diagnost continu stabl perform compani major
franchis pediatr nutrit epd core med devic high degre
convict abt prospect best-in-class organ growth
reiter outperform rate increas price target primarili
driven roll forward ntm ebitda basi one year forward
libr growth remain strong
libr mitraclip remain growth driver us lab
howev management
acknowledg fda approv libr take bit longer expect said
remain confid obtain approv includ icgm design view
collabor formal announc yesterday reinforc mitraclip
continu deliv strong growth well expect
coverag use clip patient fmr drive growth reacceler
ep guidanc narrow org guidanc ep guidanc
tighten fx expect take penni
manag call org growth around
valuat target price base ebitda multipl
unchang estim ntm ebitda one year forward bil previous bil
risk stabil epd em fx product delay
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid diversifi
healthcar product medic devic equip area
endovascular structur heart
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil grey
scenario base emerg segment deliv growth
high-growth segment grow growth grow
 close
addit detail takeaway
nutrit bil mil y/i cc
ww pediatr nutrit sale bil mil increas organ
reflect unfavor fx vs last quarter perform led
pediasur pedialyt ou growth latin america asia off-set
challeng market dynam greater china ww adult nutrit sale mil
mil increas organ perform quarter driven strong growth
ensur glucerna diabet specif nutrit brand manag expect nutrit
grow low mid singl digit
diagnost bil mil y/i
cc organ vs cse organ
laboratori diagnost sale bil mil increas
organ led above-market growth ww result continu strong adopt alin
compani receiv fda approv alinity- blood plasma screen diagnost
instrument sever test assay molecular diagnost sale mil mil
decreas organ basi similar last quarter ou sale reflect
neg impact ngo purchas pattern africa point diagnost sale
mil mil increas organ sale growth led i-stat
handheld system ou rapid diagnost sale mil mil
decreas increas organ growth led infecti diseas test
develop market cardio-metabol test ww basi partial off-set lower
expect infecti diseas test sale africa manag expect diagnost grow
mid high singl digit
establish pharma bil mil y/i
cc organ vs cse
sale key emerg market india brazil russia china increas
organ basi reflect unfavor fx last quarter em
sale increas organ sale neg impact quarter
recent discontinu suppli agreement manag expect establish pharma
grow high-singl digit
devic bil mil y/i
cc organ vs cse
electrophysiolog mil growth led strong perform cardiac diagnost
ablat cathet heart failur mil growth driven uptak heartmat
lvad follow fda approv destin long-term use therapi late growth
structur heart mil led mitraclip grew ww organ
 compani also receiv fda approv next-gen mitraclip
devic offer expand rang clip size altern leaflet grasp featur
facilit procedur assess real time offer doctor option treat
mitral valv diseas compani receiv fda approv expand indic
mitraclip treat clinic signific secondari mr result underli heart failur
compani await reimburs approv expect take month
diabet mil sale increas organ led rapid market
uptak freestyl libr report sale mil organ manag
expect medic devic growth similar organ
 oper margin slightli better expect
base analysi earn sale net cog higher sg off-set
lower deliv in-lin ep gross margin bp
estim bp last year fx neg impact bp
ep guidanc rang tighten
compani guid organ sale growth around ep fx expect
neg impact sale
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto octob
figur revenu summari varianc analysi
salesy/i chg cc cg org cg salesy/i chg cc cg org cg nutrit emer charl martineau pm univers toronto octob
chang model
decreas sale estim ep penni in-lin
new guidanc also made adjust top-lin project beyond
decreas sale estim per year averag account wors fx
also decreas ep estim beyond increas price target
driven primarili roll forward ntm ebitda basi one year forward
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
